---
title: 'CAR T-Cell Therapy in Multiple Myeloma: Mission Accomplished?'
date: '2023-11-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38033289/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231201170726&v=2.17.9.post6+86293ac
source: Blood
description: BCMA-CAR T-cells are the most potent treatment against multiple myeloma.
  Here, we review the increasing body of clinical and correlative pre-clinical data
  that support their inclusion into first-line therapy and sequencing prior to T-cell-engaging
  antibodies. The ambition to cure multiple myeloma with (BCMA-)CAR T-cells is informed
  by genomic and phenotypic analysis that assess BCMA expression for patient stratification
  and monitoring, steadily improving early diagnosis and management of ...
disable_comments: true
---
BCMA-CAR T-cells are the most potent treatment against multiple myeloma. Here, we review the increasing body of clinical and correlative pre-clinical data that support their inclusion into first-line therapy and sequencing prior to T-cell-engaging antibodies. The ambition to cure multiple myeloma with (BCMA-)CAR T-cells is informed by genomic and phenotypic analysis that assess BCMA expression for patient stratification and monitoring, steadily improving early diagnosis and management of ...